Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADME study of [14C]-rezatapopt in healthy males
NCT05523687Phase 1Completed
- Sponsor
- PMV Pharmaceuticals, Inc.
- Start
- Sep 2022
- Primary completion
- Nov 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of rezatapopt in solid tumor, sponsored by PMV Pharmaceuticals, Inc. Primary endpoints: Maximum Plasma Concentration at 1 month, Time to Maximum Plasma Concentration at 1 month and 9 more. Started Sep 2022; status: completed.
02
Drugs
rezatapopt
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT05523687.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05523687.